Neuren Pharmaceuticals (NEU) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with housekeeping and agenda overview, including CEO and Chair addresses, formal business, and Q&A session.

• Hybrid meeting format enabled global shareholder participation.

Financial performance review

• Royalty income for 2025 reached AUD 65 million, up 15% year-on-year; profit after tax was AUD 30 million.

• Cash and short-term investments rose to AUD 296 million; net cash from operations was AUD 125 million.

• Cumulative licensing income from DAYBUE reached AUD 525 million since April 2023.

• DAYBUE net sales in 2025 were $391 million, up 12%; Q1 2026 sales hit $101 million, up 20% year-on-year.

• 2026 royalty income projected at $50–54 million (AUD 70–77 million), with strong growth expected.

Board and executive committee updates

• Board and executive team introduced, including CEO, CFO, and Non-Executive Directors.

• Executive team highlighted for expertise in rare disease drug development and regulatory affairs.